

OFFICE OF THE SECRETARY OF STATE  
SHEMIA FAGAN  
SECRETARY OF STATE  
  
CHERYL MYERS  
DEPUTY SECRETARY OF STATE



ARCHIVES DIVISION  
STEPHANIE CLARK  
DIRECTOR  
  
800 SUMMER STREET NE  
SALEM, OR 97310  
503-373-0701

**NOTICE OF PROPOSED RULEMAKING**  
INCLUDING STATEMENT OF NEED & FISCAL IMPACT

CHAPTER 850  
OREGON BOARD OF NATUROPATHIC MEDICINE

**FILED**  
10/10/2022 4:14 PM  
ARCHIVES DIVISION  
SECRETARY OF STATE

FILING CAPTION: Sets out education and reporting requirements for Ketamine therapy.

LAST DAY AND TIME TO OFFER COMMENT TO AGENCY: 12/12/2022 1:00 PM

*The Agency requests public comment on whether other options should be considered for achieving the rule's substantive goals while reducing negative economic impact of the rule on business.*

*A public rulemaking hearing may be requested in writing by 10 or more people, or by a group with 10 or more members, within 21 days following the publication of the Notice of Proposed Rulemaking in the Oregon Bulletin or 28 days from the date the Notice was sent to people on the agency mailing list, whichever is later. If sufficient hearing requests are received, the notice of the date and time of the rulemaking hearing must be published in the Oregon Bulletin at least 14 days before the hearing.*

CONTACT: Mary-Beth Baptista  
971-673-0193  
marybeth.baptista@obnm.oregon.gov

800 NE Oregon Street, Ste 407  
Portland, OR 97232

Filed By:  
Mary-Beth Baptista  
Rules Coordinator

NEED FOR THE RULE(S)

Sets out education and reporting requirements for Ketamine therapy.

DOCUMENTS RELIED UPON, AND WHERE THEY ARE AVAILABLE

Formulary Council and Ketamine Subcommittee meeting minutes and supporting documentation on OBNM website.

STATEMENT IDENTIFYING HOW ADOPTION OF RULE(S) WILL AFFECT RACIAL EQUITY IN THIS STATE

No affect on racial equity in the state.

FISCAL AND ECONOMIC IMPACT:

No fiscal or economic impact.

COST OF COMPLIANCE:

*(1) Identify any state agencies, units of local government, and members of the public likely to be economically affected by the rule(s). (2) Effect on Small Businesses: (a) Estimate the number and type of small businesses subject to the rule(s); (b) Describe the expected reporting, recordkeeping and administrative activities and cost required to comply with the rule(s); (c) Estimate the cost of professional services, equipment supplies, labor and increased administration required to comply with the rule(s).*

No cost of compliance

DESCRIBE HOW SMALL BUSINESSES WERE INVOLVED IN THE DEVELOPMENT OF THESE RULE(S):

Small businesses were not affected and not involved in rule development.

WAS AN ADMINISTRATIVE RULE ADVISORY COMMITTEE CONSULTED? NO IF NOT, WHY NOT?

Formulary Council and Ketamine Subcommittee meetings were open to the public and public comment was solicited on draft rule prior to filing.

---

ADOPT: 850-060-0210

RULE SUMMARY: Sets out education and reporting requirements for Ketamine therapy.

CHANGES TO RULE:

850-060-0210

Education and Reporting Requirements for Ketamine Therapy

(1) Prior to prescribing non-topical ketamine; a Licensee must provide the Board proof of completion of four (4) hours of Board approved pharmacology education on prescribing Ketamine, including dosage and administration, clinical indications, and safety planning.¶

(2) Prior to prescribing non-topical ketamine, unless prescribing ketamine for pain management only, a Licensee must provide the Board proof of completion of two (2) hours of Board approved ethics education on Ketamine prescribing and treatment, including doctor-patient boundaries, enhanced consent, and therapy models.¶

(3) IV and Injectable Ketamine must be administered and supervised for the duration of the treatment by a Licensee who has completed the required training in Section 1 and 2. ¶

(4) Licensees may submit to the Board proof of approved education required in Section 1 and 2, earned before December 31, 2022, for approval for compliance with this rule.

Statutory/Other Authority: 685.106, 685.102

Statutes/Other Implemented: 685.106, 685.102